Two EHA abstracts
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: Two EHA abstracts
Thanks for posting, BP.
*clinical efficacy* of imetelstat in **molecularly defined patient subtypes
**I have been referencing **molecularly defined patient subtypes for some time. This is critical, and imo... can only lead to **better** Phase III performance, as clinicians decide whether to recommend the Imerge trial to their patients.
*clinical efficacy* of imetelstat in **molecularly defined patient subtypes
**I have been referencing **molecularly defined patient subtypes for some time. This is critical, and imo... can only lead to **better** Phase III performance, as clinicians decide whether to recommend the Imerge trial to their patients.
-
biopearl123
- Posts: 1669
- Joined: Fri Jul 20, 2018 5:13 pm
Re: Two EHA abstracts
Ryan, I agree. Pretty clear from abstract that efficacy can be predicted on basis of number and type of mutations. Also for those looking for bone marrow normalization, it seems clear from Dr. Rizo's comments that "complete remission" may not be present by current definitions even in patients with prolonged TI, the implication being that TI's have bone marrow improvement but for those looking for "cure", that may not be realistic. The bottom line is TI is the sought after goal and Geron is achieving that. Interesting that there is no update on the TI patients continued duration (or not). Wonder if that will come out at the meeting. Dr. Rizo clear in stating that Imetelstat is differentiated and unique in ability to selectively attack malignant stem and progenitor cells, that is big. bp